메뉴 건너뛰기




Volumn 16, Issue 2, 2010, Pages 155-163

Pharmacogenetics in oncology: A promising field

Author keywords

Oncology; Pharmacogenetics; Pharmacogenomics; Single nucleotide polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ABC TRANSPORTER; ABC TRANSPORTER A1; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DNA; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE; IRINOTECAN; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PLATINUM; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TIOGUANINE; XRCC1 PROTEIN;

EID: 77949434181     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790112719     Document Type: Review
Times cited : (19)

References (152)
  • 1
    • 52549118408 scopus 로고    scopus 로고
    • Somatic pharmacogenomics in cancer
    • Ikediobi ON. Somatic pharmacogenomics in cancer. Pharmacogenomics J 2008; 8(5): 305-14.
    • (2008) Pharmacogenomics J , vol.8 , Issue.5 , pp. 305-314
    • Ikediobi, O.N.1
  • 2
    • 34250850778 scopus 로고    scopus 로고
    • Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs
    • Pander J, Gelderblom H, Guchelaar HJ. Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. Expert Opin Pharmacother 2007; 8(9): 1197-210.
    • (2007) Expert Opin Pharmacother , vol.8 , Issue.9 , pp. 1197-1210
    • Pander, J.1    Gelderblom, H.2    Guchelaar, H.J.3
  • 6
    • 0023902287 scopus 로고
    • Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
    • Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81(1): 47-51.
    • (1988) J Clin Invest , vol.81 , Issue.1 , pp. 47-51
    • Diasio, R.B.1    Beavers, T.L.2    Carpenter, J.T.3
  • 7
    • 0031928495 scopus 로고    scopus 로고
    • Population and family studies of dihydropyrimidinuria: Prevalence, inheritance mode, and risk of fluorouracil toxicity
    • Sumi S, Imaeda M, Kidouchi K, Ohba S, Hamajima N, Kodama K, et al. Population and family studies of dihydropyrimidinuria: prevalence, inheritance mode, and risk of fluorouracil toxicity. Am J Med Genet 1998; 78(4): 336-40.
    • (1998) Am J Med Genet , vol.78 , Issue.4 , pp. 336-340
    • Sumi, S.1    Imaeda, M.2    Kidouchi, K.3    Ohba, S.4    Hamajima, N.5    Kodama, K.6
  • 10
    • 0032422075 scopus 로고    scopus 로고
    • Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity
    • Kouwaki M, Hamajima N, Sumi S, Nonaka M, Sasaki M, Dobashi K, et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 1998; 4(12): 2999-3004.
    • (1998) Clin Cancer Res , vol.4 , Issue.12 , pp. 2999-3004
    • Kouwaki, M.1    Hamajima, N.2    Sumi, S.3    Nonaka, M.4    Sasaki, M.5    Dobashi, K.6
  • 11
    • 0034488052 scopus 로고    scopus 로고
    • Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
    • van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van LH, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6(12): 4705-12.
    • (2000) Clin Cancer Res , vol.6 , Issue.12 , pp. 4705-4712
    • van Kuilenburg, A.B.1    Haasjes, J.2    Richel, D.J.3    Zoetekouw, L.4    Van, L.H.5    De Abreu, R.A.6
  • 12
    • 0034901306 scopus 로고    scopus 로고
    • Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+ 1G>A mutation causing DPD deficiency
    • van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+ 1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7(5): 1149-53.
    • (2001) Clin Cancer Res , vol.7 , Issue.5 , pp. 1149-1153
    • van Kuilenburg, A.B.1    Muller, E.W.2    Haasjes, J.3    Meinsma, R.4    Zoetekouw, L.5    Waterham, H.R.6
  • 13
    • 0034808681 scopus 로고    scopus 로고
    • Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
    • Raida M, Schwabe W, Hausler P, van Kuilenburg AB, van Gennip AH, Behnke D, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7(9): 2832-9.
    • (2001) Clin Cancer Res , vol.7 , Issue.9 , pp. 2832-2839
    • Raida, M.1    Schwabe, W.2    Hausler, P.3    van Kuilenburg, A.B.4    van Gennip, A.H.5    Behnke, D.6
  • 14
    • 0036798968 scopus 로고    scopus 로고
    • High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity
    • van Kuilenburg AB, Meinsma R, Zoetekouw L, van Gennip AH. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12(7): 555-8.
    • (2002) Pharmacogenetics , vol.12 , Issue.7 , pp. 555-558
    • van Kuilenburg, A.B.1    Meinsma, R.2    Zoetekouw, L.3    van Gennip, A.H.4
  • 15
    • 0037144354 scopus 로고    scopus 로고
    • Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation
    • van Kuilenburg AB, Meinsma R, Zoetekouw L, van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 2002; 101(3): 253-8.
    • (2002) Int J Cancer , vol.101 , Issue.3 , pp. 253-258
    • van Kuilenburg, A.B.1    Meinsma, R.2    Zoetekouw, L.3    van Gennip, A.H.4
  • 16
    • 25144509570 scopus 로고    scopus 로고
    • Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function
    • van Kuilenburg AB, Meinsma R, Beke E, Bobba B, Boffi P, Enns GM, et al. Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function. Biol Chem 2005; 386(4): 319-24.
    • (2005) Biol Chem , vol.386 , Issue.4 , pp. 319-324
    • van Kuilenburg, A.B.1    Meinsma, R.2    Beke, E.3    Bobba, B.4    Boffi, P.5    Enns, G.M.6
  • 17
    • 0034050905 scopus 로고    scopus 로고
    • Known variant DPYD alleles do not explain DPD deficiency in cancer patients
    • Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10(3): 217-23.
    • (2000) Pharmacogenetics , vol.10 , Issue.3 , pp. 217-223
    • Collie-Duguid, E.S.1    Etienne, M.C.2    Milano, G.3    McLeod, H.L.4
  • 18
    • 23844456590 scopus 로고    scopus 로고
    • Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals
    • Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 2005; 11(16): 5886-92.
    • (2005) Clin Cancer Res , vol.11 , Issue.16 , pp. 5886-5892
    • Seck, K.1    Riemer, S.2    Kates, R.3    Ullrich, T.4    Lutz, V.5    Harbeck, N.6
  • 19
    • 29344443013 scopus 로고    scopus 로고
    • Methylation of the DPYD promoter: An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients
    • Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005; 11(24 Pt 1): 8699-705.
    • (2005) Clin Cancer Res , vol.11 , Issue.24 PART 1 , pp. 8699-8705
    • Ezzeldin, H.H.1    Lee, A.M.2    Mattison, L.K.3    Diasio, R.B.4
  • 20
    • 33947587702 scopus 로고    scopus 로고
    • Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: A potentially important epigenetic mechanism regulating DPYD expression
    • Zhang X, Soong R, Wang K, Li L, Davie JR, Guarcello V, et al. Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. Biochem Cell Biol 2007; 85(3): 337-46.
    • (2007) Biochem Cell Biol , vol.85 , Issue.3 , pp. 337-346
    • Zhang, X.1    Soong, R.2    Wang, K.3    Li, L.4    Davie, J.R.5    Guarcello, V.6
  • 21
    • 56349087342 scopus 로고    scopus 로고
    • Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluororuacil based chemotherapy
    • Amstutz U, Farese S, Aebi S, Largiader CR. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluororuacil based chemotherapy. J Exp Clin Cancer Res 2008; 27(1): 54.
    • (2008) J Exp Clin Cancer Res , vol.27 , Issue.1 , pp. 54
    • Amstutz, U.1    Farese, S.2    Aebi, S.3    Largiader, C.R.4
  • 22
    • 37449002083 scopus 로고    scopus 로고
    • Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: Experience of 4-years
    • Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: experience of 4-years. Pak J Med Sci Q 2007; 23(6): 832-9.
    • (2007) Pak J Med Sci Q , vol.23 , Issue.6 , pp. 832-839
    • Saif, M.W.1    Syrigos, K.2    Mehra, R.3    Mattison, L.K.4    Diasio, R.B.5
  • 23
    • 43749114271 scopus 로고    scopus 로고
    • Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group
    • Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26(13): 2131-8.
    • (2008) J Clin Oncol , vol.26 , Issue.13 , pp. 2131-2138
    • Schwab, M.1    Zanger, U.M.2    Marx, C.3    Schaeffeler, E.4    Klein, K.5    Dippon, J.6
  • 24
    • 47049088370 scopus 로고    scopus 로고
    • Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase
    • Lazar A, Jetter A. Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase. Dtsch Med Wochenschr 2008; 133(28-29): 1501-4.
    • (2008) Dtsch Med Wochenschr , vol.133 , Issue.28-29 , pp. 1501-1504
    • Lazar, A.1    Jetter, A.2
  • 25
    • 33845219798 scopus 로고    scopus 로고
    • Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
    • Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5(11): 2895-904.
    • (2006) Mol Cancer Ther , vol.5 , Issue.11 , pp. 2895-2904
    • Morel, A.1    Boisdron-Celle, M.2    Fey, L.3    Soulie, P.4    Craipeau, M.C.5    Traore, S.6
  • 26
    • 37549027579 scopus 로고    scopus 로고
    • Uzunkoy A, Dilmec F, Ozgonul A, van Kuilenburg AB, Akkafa F. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer. Anticancer Res 2007; 27(6B): 3899-02.
    • Uzunkoy A, Dilmec F, Ozgonul A, van Kuilenburg AB, Akkafa F. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer. Anticancer Res 2007; 27(6B): 3899-02.
  • 27
    • 35548993299 scopus 로고    scopus 로고
    • Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity
    • Lazar A, Grundemann D, Schomig E. Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. Mol Diagn Ther 2007; 11(5): 341-2.
    • (2007) Mol Diagn Ther , vol.11 , Issue.5 , pp. 341-342
    • Lazar, A.1    Grundemann, D.2    Schomig, E.3
  • 28
    • 33947588763 scopus 로고    scopus 로고
    • Should DPD analysis be required prior to prescribing fluoropyrimidines?
    • Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007; 43(6): 1011-6.
    • (2007) Eur J Cancer , vol.43 , Issue.6 , pp. 1011-1016
    • Yen, J.L.1    McLeod, H.L.2
  • 29
    • 0029052988 scopus 로고
    • Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil
    • Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995; 49(10): 1419-26.
    • (1995) Biochem Pharmacol , vol.49 , Issue.10 , pp. 1419-1426
    • Copur, S.1    Aiba, K.2    Drake, J.C.3    Allegra, C.J.4    Chu, E.5
  • 30
    • 0024437529 scopus 로고
    • Human thymidylate synthase gene: Isolation of phage clones which cover a functionally active gene and structural analysis of the region upstream from the translation initiation codon
    • Takeishi K, Kaneda S, Ayusawa D, Shimizu K, Gotoh O, Seno T. Human thymidylate synthase gene: isolation of phage clones which cover a functionally active gene and structural analysis of the region upstream from the translation initiation codon. J Biochem 1989; 106(4): 575-83.
    • (1989) J Biochem , vol.106 , Issue.4 , pp. 575-583
    • Takeishi, K.1    Kaneda, S.2    Ayusawa, D.3    Shimizu, K.4    Gotoh, O.5    Seno, T.6
  • 31
    • 0029122937 scopus 로고
    • Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase
    • Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20(3): 191-7.
    • (1995) Cell Struct Funct , vol.20 , Issue.3 , pp. 191-197
    • Horie, N.1    Aiba, H.2    Oguro, K.3    Hojo, H.4    Takeishi, K.5
  • 32
    • 0035671827 scopus 로고    scopus 로고
    • Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression
    • Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001; 7(12): 4096-101.
    • (2001) Clin Cancer Res , vol.7 , Issue.12 , pp. 4096-4101
    • Kawakami, K.1    Salonga, D.2    Park, J.M.3    Danenberg, K.D.4    Uetake, H.5    Brabender, J.6
  • 33
    • 0036868961 scopus 로고    scopus 로고
    • Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity
    • Kawakami K, Ishida Y, Danenberg KD, Omura K, Watanabe G, Danenberg PV. Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity. Jpn J Cancer Res 2002; 93(11): 1221-9.
    • (2002) Jpn J Cancer Res , vol.93 , Issue.11 , pp. 1221-1229
    • Kawakami, K.1    Ishida, Y.2    Danenberg, K.D.3    Omura, K.4    Watanabe, G.5    Danenberg, P.V.6
  • 34
    • 0842268401 scopus 로고    scopus 로고
    • Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene
    • Uchida K, Hayashi K, Kawakami K, Schneider S, Yochim JM, Kuramochi H, et al. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 2004; 10(2): 433-9.
    • (2004) Clin Cancer Res , vol.10 , Issue.2 , pp. 433-439
    • Uchida, K.1    Hayashi, K.2    Kawakami, K.3    Schneider, S.4    Yochim, J.M.5    Kuramochi, H.6
  • 35
    • 25144481273 scopus 로고    scopus 로고
    • Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil
    • Hitre E, Budai B, Adleff V, Czegledi F, Horvath Z, Gyergyay F, et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005; 15(10): 723-30.
    • (2005) Pharmacogenet Genomics , vol.15 , Issue.10 , pp. 723-730
    • Hitre, E.1    Budai, B.2    Adleff, V.3    Czegledi, F.4    Horvath, Z.5    Gyergyay, F.6
  • 36
    • 14944380124 scopus 로고    scopus 로고
    • Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity
    • Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23(7): 1365-9.
    • (2005) J Clin Oncol , vol.23 , Issue.7 , pp. 1365-1369
    • Jakobsen, A.1    Nielsen, J.N.2    Gyldenkerne, N.3    Lindeberg, J.4
  • 37
    • 0037567591 scopus 로고    scopus 로고
    • A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity
    • Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63(11): 2898-904.
    • (2003) Cancer Res , vol.63 , Issue.11 , pp. 2898-2904
    • Mandola, M.V.1    Stoehlmacher, J.2    Muller-Weeks, S.3    Cesarone, G.4    Yu, M.C.5    Lenz, H.J.6
  • 38
    • 25144517063 scopus 로고    scopus 로고
    • Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers
    • Morganti M, Ciantelli M, Giglioni B, Putignano AL, Nobili S, Papi L, et al. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 2005; 41(14): 2176-83.
    • (2005) Eur J Cancer , vol.41 , Issue.14 , pp. 2176-2183
    • Morganti, M.1    Ciantelli, M.2    Giglioni, B.3    Putignano, A.L.4    Nobili, S.5    Papi, L.6
  • 39
    • 33645750172 scopus 로고    scopus 로고
    • Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment
    • Dotor E, Cuatrecases M, Martinez-Iniesta M, Navarro M, Vilardell F, Guino E, et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24(10): 1603-11.
    • (2006) J Clin Oncol , vol.24 , Issue.10 , pp. 1603-1611
    • Dotor, E.1    Cuatrecases, M.2    Martinez-Iniesta, M.3    Navarro, M.4    Vilardell, F.5    Guino, E.6
  • 40
    • 7244258790 scopus 로고    scopus 로고
    • Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracilbased chemotherapy in advanced colorectal cancer patients
    • Marcuello E, Altes A, del RE, Cesar A, Menoyo A, Baiget M. Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracilbased chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004; 112(5): 733-7.
    • (2004) Int J Cancer , vol.112 , Issue.5 , pp. 733-737
    • Marcuello, E.1    Altes, A.2    del, R.E.3    Cesar, A.4    Menoyo, A.5    Baiget, M.6
  • 41
    • 4444339951 scopus 로고    scopus 로고
    • Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy
    • Lecomte T, Ferraz JM, Zinzindohoue F, Loriot MA, Tregouet DA, Landi B, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10(17): 5880-8.
    • (2004) Clin Cancer Res , vol.10 , Issue.17 , pp. 5880-5888
    • Lecomte, T.1    Ferraz, J.M.2    Zinzindohoue, F.3    Loriot, M.A.4    Tregouet, D.A.5    Landi, B.6
  • 42
    • 55949090530 scopus 로고    scopus 로고
    • Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation
    • Stoehlmacher J, Goekkurt E, Mogck U, Aust DE, Kramer M, Baretton GB, et al. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Lett 2008; 272(2): 221-5.
    • (2008) Cancer Lett , vol.272 , Issue.2 , pp. 221-225
    • Stoehlmacher, J.1    Goekkurt, E.2    Mogck, U.3    Aust, D.E.4    Kramer, M.5    Baretton, G.B.6
  • 43
    • 2442480694 scopus 로고    scopus 로고
    • A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels
    • Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004; 14(5): 319-27.
    • (2004) Pharmacogenetics , vol.14 , Issue.5 , pp. 319-327
    • Mandola, M.V.1    Stoehlmacher, J.2    Zhang, W.3    Groshen, S.4    Yu, M.C.5    Iqbal, S.6
  • 44
    • 59249103886 scopus 로고    scopus 로고
    • Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer
    • Li Y, Li X, Dai H, Sun X, Li J, Yang F, et al. Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer. BJU Int 2008; 103(4): 547-52.
    • (2008) BJU Int , vol.103 , Issue.4 , pp. 547-552
    • Li, Y.1    Li, X.2    Dai, H.3    Sun, X.4    Li, J.5    Yang, F.6
  • 45
    • 67349155299 scopus 로고    scopus 로고
    • Polymorphisms of Thymidylate Synthase in the 5′- and 3′-Untranslated Regions and Gastric Cancer
    • Zhuang W, Wu XT, Zhou Y, Liu GJ, Wu TX, Yao X, et al. Polymorphisms of Thymidylate Synthase in the 5′- and 3′-Untranslated Regions and Gastric Cancer. Dig Dis Sci 2008; 54(7): 1379-85.
    • (2008) Dig Dis Sci , vol.54 , Issue.7 , pp. 1379-1385
    • Zhuang, W.1    Wu, X.T.2    Zhou, Y.3    Liu, G.J.4    Wu, T.X.5    Yao, X.6
  • 46
    • 58149312988 scopus 로고    scopus 로고
    • Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy
    • Tateishi Y, Tatemoto Y, Ohno S, Morishita K, Ueta E, Yamamoto T. Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy. Cancer Lett 2008; 274(2): 187-93.
    • (2008) Cancer Lett , vol.274 , Issue.2 , pp. 187-193
    • Tateishi, Y.1    Tatemoto, Y.2    Ohno, S.3    Morishita, K.4    Ueta, E.5    Yamamoto, T.6
  • 47
    • 53449098390 scopus 로고    scopus 로고
    • Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: Evidence from 24 studies
    • Qiu LX, Tang QY, Bai JL, Qian XP, Li RT, Liu BR, et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 2008; 123(10): 2384-9.
    • (2008) Int J Cancer , vol.123 , Issue.10 , pp. 2384-2389
    • Qiu, L.X.1    Tang, Q.Y.2    Bai, J.L.3    Qian, X.P.4    Li, R.T.5    Liu, B.R.6
  • 48
    • 50249189069 scopus 로고    scopus 로고
    • Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
    • Graziano F, Ruzzo A, Loupakis F, Santini D, Catalano V, Canestrari E, et al. Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. Br J Cancer 2008; 99(5): 716-21.
    • (2008) Br J Cancer , vol.99 , Issue.5 , pp. 716-721
    • Graziano, F.1    Ruzzo, A.2    Loupakis, F.3    Santini, D.4    Catalano, V.5    Canestrari, E.6
  • 49
    • 52749090632 scopus 로고    scopus 로고
    • Transcription factor-binding sites in the thymidylate synthase gene: Predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?
    • Pare L, Marcuello E, Altes A, del RE, Sedano L, Barnadas A, et al. Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin? Pharmacogenomics J 2008; 8(5): 315-20.
    • (2008) Pharmacogenomics J , vol.8 , Issue.5 , pp. 315-320
    • Pare, L.1    Marcuello, E.2    Altes, A.3    del, R.E.4    Sedano, L.5    Barnadas, A.6
  • 50
    • 1042292043 scopus 로고    scopus 로고
    • Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate
    • Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96(2): 134-44.
    • (2004) J Natl Cancer Inst , vol.96 , Issue.2 , pp. 134-144
    • Sohn, K.J.1    Croxford, R.2    Yates, Z.3    Lucock, M.4    Kim, Y.I.5
  • 51
    • 0036928840 scopus 로고    scopus 로고
    • Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate
    • Chiusolo P, Reddiconto G, Casorelli I, Laurenti L, Sora F, Mele L, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002; 13(12): 1915-8.
    • (2002) Ann Oncol , vol.13 , Issue.12 , pp. 1915-1918
    • Chiusolo, P.1    Reddiconto, G.2    Casorelli, I.3    Laurenti, L.4    Sora, F.5    Mele, L.6
  • 52
    • 0037454801 scopus 로고    scopus 로고
    • Effect of methylenetetrahydrofolate reductase 677C - >T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients
    • Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, et al. Effect of methylenetetrahydrofolate reductase 677C - >T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103(3): 294-9.
    • (2003) Int J Cancer , vol.103 , Issue.3 , pp. 294-299
    • Toffoli, G.1    Russo, A.2    Innocenti, F.3    Corona, G.4    Tumolo, S.5    Sartor, F.6
  • 53
    • 0037990003 scopus 로고    scopus 로고
    • Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy
    • Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9(5): 1611-5.
    • (2003) Clin Cancer Res , vol.9 , Issue.5 , pp. 1611-1615
    • Cohen, V.1    Panet-Raymond, V.2    Sabbaghian, N.3    Morin, I.4    Batist, G.5    Rozen, R.6
  • 54
    • 61449259904 scopus 로고    scopus 로고
    • The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population
    • Huang ZH, Hua D, Li LH. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Cancer Chemother Pharmacol 2009; 63(5): 911-8.
    • (2009) Cancer Chemother Pharmacol , vol.63 , Issue.5 , pp. 911-918
    • Huang, Z.H.1    Hua, D.2    Li, L.H.3
  • 55
    • 33645727994 scopus 로고    scopus 로고
    • Methylene- tetrahydrofolate reductase gene polymorphisms: Genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
    • Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M. Methylene- tetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 2006; 57(6): 835-40.
    • (2006) Cancer Chemother Pharmacol , vol.57 , Issue.6 , pp. 835-840
    • Marcuello, E.1    Altes, A.2    Menoyo, A.3    Rio, E.D.4    Baiget, M.5
  • 56
    • 37349058652 scopus 로고    scopus 로고
    • Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer
    • Etienne-Grimaldi MC, Francoual M, Formento JL, Milano G. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics 2007; 8(11): 1561-6.
    • (2007) Pharmacogenomics , vol.8 , Issue.11 , pp. 1561-1566
    • Etienne-Grimaldi, M.C.1    Francoual, M.2    Formento, J.L.3    Milano, G.4
  • 57
    • 19944428095 scopus 로고    scopus 로고
    • Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients
    • Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14(12): 785-92.
    • (2004) Pharmacogenetics , vol.14 , Issue.12 , pp. 785-792
    • Etienne, M.C.1    Formento, J.L.2    Chazal, M.3    Francoual, M.4    Magne, N.5    Formento, P.6
  • 58
    • 18844408403 scopus 로고    scopus 로고
    • MTHFR genotypes and breast cancer survival after surgery and chemotherapy: A report from the Shanghai Breast Cancer Study
    • Shrubsole MJ, Shu XO, Ruan ZX, Cai Q, Cai H, Niu Q, et al. MTHFR genotypes and breast cancer survival after surgery and chemotherapy: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 2005; 91(1): 73-9.
    • (2005) Breast Cancer Res Treat , vol.91 , Issue.1 , pp. 73-79
    • Shrubsole, M.J.1    Shu, X.O.2    Ruan, Z.X.3    Cai, Q.4    Cai, H.5    Niu, Q.6
  • 59
    • 31544458716 scopus 로고    scopus 로고
    • The thiopurines: An update
    • Coulthard S, Hogarth L. The thiopurines: an update. Invest New Drugs 2005; 23(6): 523-32.
    • (2005) Invest New Drugs , vol.23 , Issue.6 , pp. 523-532
    • Coulthard, S.1    Hogarth, L.2
  • 61
    • 0027308959 scopus 로고
    • The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts
    • Vogt MH, Stet EH, De Abreu RA, Bokkerink JP, Lambooy LH, Trijbels FJ. The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts. Biochim Biophys Acta 1993; 1181(2): 189-94.
    • (1993) Biochim Biophys Acta , vol.1181 , Issue.2 , pp. 189-194
    • Vogt, M.H.1    Stet, E.H.2    De Abreu, R.A.3    Bokkerink, J.P.4    Lambooy, L.H.5    Trijbels, F.J.6
  • 62
    • 0018822866 scopus 로고
    • Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
    • Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32(5): 651-62.
    • (1980) Am J Hum Genet , vol.32 , Issue.5 , pp. 651-662
    • Weinshilboum, R.M.1    Sladek, S.L.2
  • 63
    • 0028930908 scopus 로고
    • Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia
    • McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995; 85(7): 1897-902.
    • (1995) Blood , vol.85 , Issue.7 , pp. 1897-1902
    • McLeod, H.L.1    Relling, M.V.2    Liu, Q.3    Pui, C.H.4    Evans, W.E.5
  • 64
    • 0025331198 scopus 로고
    • Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
    • Lennard L, Lilleyman JS, Van LJ, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336(8709): 225-9.
    • (1990) Lancet , vol.336 , Issue.8709 , pp. 225-229
    • Lennard, L.1    Lilleyman, J.S.2    Van, L.J.3    Weinshilboum, R.M.4
  • 65
    • 0035871560 scopus 로고    scopus 로고
    • Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine
    • Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19(8): 2293-301.
    • (2001) J Clin Oncol , vol.19 , Issue.8 , pp. 2293-2301
    • Evans, W.E.1    Hon, Y.Y.2    Bomgaars, L.3    Coutre, S.4    Holdsworth, M.5    Janco, R.6
  • 66
    • 0033135738 scopus 로고    scopus 로고
    • Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
    • Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999; 93(9): 2817-23.
    • (1999) Blood , vol.93 , Issue.9 , pp. 2817-2823
    • Relling, M.V.1    Hancock, M.L.2    Boyett, J.M.3    Pui, C.H.4    Evans, W.E.5
  • 68
    • 3242762099 scopus 로고    scopus 로고
    • Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants
    • Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14(7): 407-17.
    • (2004) Pharmacogenetics , vol.14 , Issue.7 , pp. 407-417
    • Schaeffeler, E.1    Fischer, C.2    Brockmeier, D.3    Wernet, D.4    Moerike, K.5    Eichelbaum, M.6
  • 69
    • 0027524983 scopus 로고
    • Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia
    • Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 69(5): 577-9.
    • (1993) Arch Dis Child , vol.69 , Issue.5 , pp. 577-579
    • Lennard, L.1    Gibson, B.E.2    Nicole, T.3    Lilleyman, J.S.4
  • 70
    • 0029919807 scopus 로고    scopus 로고
    • Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians
    • Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58(4): 694-702.
    • (1996) Am J Hum Genet , vol.58 , Issue.4 , pp. 694-702
    • Tai, H.L.1    Krynetski, E.Y.2    Yates, C.R.3    Loennechen, T.4    Fessing, M.Y.5    Krynetskaia, N.F.6
  • 71
    • 0030048791 scopus 로고    scopus 로고
    • Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism
    • Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15(1): 17-30.
    • (1996) DNA Cell Biol , vol.15 , Issue.1 , pp. 17-30
    • Szumlanski, C.1    Otterness, D.2    Her, C.3    Lee, D.4    Brandriff, B.5    Kelsell, D.6
  • 72
    • 0030986251 scopus 로고    scopus 로고
    • Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity
    • Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997; 94(12): 6444-9.
    • (1997) Proc Natl Acad Sci USA , vol.94 , Issue.12 , pp. 6444-6449
    • Tai, H.L.1    Krynetski, E.Y.2    Schuetz, E.G.3    Yanishevski, Y.4    Evans, W.E.5
  • 74
    • 0032917646 scopus 로고    scopus 로고
    • The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
    • Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9(1): 37-42.
    • (1999) Pharmacogenetics , vol.9 , Issue.1 , pp. 37-42
    • Collie-Duguid, E.S.1    Pritchard, S.C.2    Powrie, R.H.3    Sludden, J.4    Collier, D.A.5    Li, T.6
  • 75
    • 0033434009 scopus 로고    scopus 로고
    • Ethnic differences in thiopurine methyltransferase pharmacogenetics: Evidence for allele specificity in Caucasian and Kenyan individuals
    • McLeod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw MM, Powrie RH, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999; 9(6): 773-6.
    • (1999) Pharmacogenetics , vol.9 , Issue.6 , pp. 773-776
    • McLeod, H.L.1    Pritchard, S.C.2    Githang'a, J.3    Indalo, A.4    Ameyaw, M.M.5    Powrie, R.H.6
  • 76
    • 0034646283 scopus 로고    scopus 로고
    • Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population
    • Hiratsuka M, Inoue T, Omori F, Agatsuma Y, Mizugaki M. Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat Res 2000; 448(1): 91-5.
    • (2000) Mutat Res , vol.448 , Issue.1 , pp. 91-95
    • Hiratsuka, M.1    Inoue, T.2    Omori, F.3    Agatsuma, Y.4    Mizugaki, M.5
  • 77
    • 0035052283 scopus 로고    scopus 로고
    • Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukaemia
    • Ando M, Ando Y, Hasegawa Y, Sekido Y, Shimokata K, Horibe K. Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukaemia. Pharmacogenetics 2001; 11(3): 269-73.
    • (2001) Pharmacogenetics , vol.11 , Issue.3 , pp. 269-273
    • Ando, M.1    Ando, Y.2    Hasegawa, Y.3    Sekido, Y.4    Shimokata, K.5    Horibe, K.6
  • 78
    • 33645127229 scopus 로고    scopus 로고
    • Molecular analysis of thiopurine S-methyltransferase alleles in Taiwan aborigines and Taiwanese
    • Lu HF, Shih MC, Chang YS, Chang JY, Ko YC, Chang SJ, et al. Molecular analysis of thiopurine S-methyltransferase alleles in Taiwan aborigines and Taiwanese. J Clin Pharm Ther 2006; 31(1): 93-8.
    • (2006) J Clin Pharm Ther , vol.31 , Issue.1 , pp. 93-98
    • Lu, H.F.1    Shih, M.C.2    Chang, Y.S.3    Chang, J.Y.4    Ko, Y.C.5    Chang, S.J.6
  • 79
    • 33750581390 scopus 로고    scopus 로고
    • Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function
    • Schaeffeler E, Eichelbaum M, Reinisch W, Zanger UM, Schwab M. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum Mutat 2006; 27(9): 976.
    • (2006) Hum Mutat , vol.27 , Issue.9 , pp. 976
    • Schaeffeler, E.1    Eichelbaum, M.2    Reinisch, W.3    Zanger, U.M.4    Schwab, M.5
  • 80
    • 0030934850 scopus 로고    scopus 로고
    • Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
    • Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126(8): 608-14.
    • (1997) Ann Intern Med , vol.126 , Issue.8 , pp. 608-614
    • Yates, C.R.1    Krynetski, E.Y.2    Loennechen, T.3    Fessing, M.Y.4    Tai, H.L.5    Pui, C.H.6
  • 81
    • 20144365645 scopus 로고    scopus 로고
    • Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia
    • Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005; 293(12): 1485-9.
    • (2005) JAMA , vol.293 , Issue.12 , pp. 1485-1489
    • Stanulla, M.1    Schaeffeler, E.2    Flohr, T.3    Cario, G.4    Schrauder, A.5    Zimmermann, M.6
  • 82
    • 33747168764 scopus 로고    scopus 로고
    • Cost-effectiveness of pharmacogenomics in clinical practice: A case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe
    • van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez de ME, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006; 7(5): 783-92.
    • (2006) Pharmacogenomics , vol.7 , Issue.5 , pp. 783-792
    • van den Akker-van Marle, M.E.1    Gurwitz, D.2    Detmar, S.B.3    Enzing, C.M.4    Hopkins, M.M.5    Gutierrez de, M.E.6
  • 83
    • 34547523374 scopus 로고    scopus 로고
    • Should we test TPMT enzyme levels before starting azathioprine?
    • Richard VS, Al-Ismail D, Salamat A. Should we test TPMT enzyme levels before starting azathioprine? Hematology 2007; 12(4): 359-60.
    • (2007) Hematology , vol.12 , Issue.4 , pp. 359-360
    • Richard, V.S.1    Al-Ismail, D.2    Salamat, A.3
  • 84
    • 46749126229 scopus 로고    scopus 로고
    • Avoiding adverse drug reactions by pharmacogenetic testing: A systematic review of the economic evidence in the case of TPMT and AZA-induced side effects
    • Compagni A, Bartoli S, Buehrlen B, Fattore G, Ibarreta D, de Mesa EG. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int J Technol Assess Health Care 2008; 24(3): 294-302.
    • (2008) Int J Technol Assess Health Care , vol.24 , Issue.3 , pp. 294-302
    • Compagni, A.1    Bartoli, S.2    Buehrlen, B.3    Fattore, G.4    Ibarreta, D.5    de Mesa, E.G.6
  • 85
    • 57149132666 scopus 로고    scopus 로고
    • Thiopurine S-methyltransferase pharmacogenetics: Autophagy as a mechanism for variant allozyme degradation
    • Li F, Wang L, Burgess RJ, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. Pharmacogenet Genomics 2008; 18(12): 1083-94.
    • (2008) Pharmacogenet Genomics , vol.18 , Issue.12 , pp. 1083-1094
    • Li, F.1    Wang, L.2    Burgess, R.J.3    Weinshilboum, R.M.4
  • 86
    • 0030030762 scopus 로고    scopus 로고
    • Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome
    • Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347(9001): 578-81.
    • (1996) Lancet , vol.347 , Issue.9001 , pp. 578-581
    • Monaghan, G.1    Ryan, M.2    Seddon, R.3    Hume, R.4    Burchell, B.5
  • 87
    • 0026701911 scopus 로고
    • A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini
    • Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 1992; 267(5): 3257-61.
    • (1992) J Biol Chem , vol.267 , Issue.5 , pp. 3257-3261
    • Ritter, J.K.1    Chen, F.2    Sheen, Y.Y.3    Tran, H.M.4    Kimura, S.5    Yeatman, M.T.6
  • 88
    • 0033799997 scopus 로고    scopus 로고
    • Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: Correlation of genotype to phenotype
    • Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000; 16(4): 297-306.
    • (2000) Hum Mutat , vol.16 , Issue.4 , pp. 297-306
    • Kadakol, A.1    Ghosh, S.S.2    Sappal, B.S.3    Sharma, G.4    Chowdhury, J.R.5    Chowdhury, N.R.6
  • 89
    • 18444399926 scopus 로고    scopus 로고
    • Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia
    • Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M, et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 2002; 292(2): 492-7.
    • (2002) Biochem Biophys Res Commun , vol.292 , Issue.2 , pp. 492-497
    • Sugatani, J.1    Yamakawa, K.2    Yoshinari, K.3    Machida, T.4    Takagi, H.5    Mori, M.6
  • 90
    • 0036765309 scopus 로고    scopus 로고
    • Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)
    • Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62(3): 608-17.
    • (2002) Mol Pharmacol , vol.62 , Issue.3 , pp. 608-617
    • Gagne, J.F.1    Montminy, V.2    Belanger, P.3    Journault, K.4    Gaucher, G.5    Guillemette, C.6
  • 91
    • 0028867826 scopus 로고
    • The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
    • Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de BA, Oostra BA et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333(18): 1171-5.
    • (1995) N Engl J Med , vol.333 , Issue.18 , pp. 1171-1175
    • Bosma, P.J.1    Chowdhury, J.R.2    Bakker, C.3    Gantla, S.4    de, B.A.5    Oostra, B.A.6
  • 92
    • 0034671387 scopus 로고    scopus 로고
    • Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
    • Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60(24): 6921-6.
    • (2000) Cancer Res , vol.60 , Issue.24 , pp. 6921-6926
    • Ando, Y.1    Saka, H.2    Ando, M.3    Sawa, T.4    Muro, K.5    Ueoka, H.6
  • 93
    • 12944329893 scopus 로고    scopus 로고
    • UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan
    • Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11(3): 1226-36.
    • (2005) Clin Cancer Res , vol.11 , Issue.3 , pp. 1226-1236
    • Carlini, L.E.1    Meropol, N.J.2    Bever, J.3    Andria, M.L.4    Hill, T.5    Gold, P.6
  • 94
    • 2342459714 scopus 로고    scopus 로고
    • Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
    • Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22(8): 1382-8.
    • (2004) J Clin Oncol , vol.22 , Issue.8 , pp. 1382-1388
    • Innocenti, F.1    Undevia, S.D.2    Iyer, L.3    Chen, P.X.4    Das, S.5    Kocherginsky, M.6
  • 95
    • 33644525291 scopus 로고    scopus 로고
    • Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy
    • Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006; 106(5): 1007-16.
    • (2006) Cancer , vol.106 , Issue.5 , pp. 1007-1016
    • Massacesi, C.1    Terrazzino, S.2    Marcucci, F.3    Rocchi, M.B.4    Lippe, P.5    Bisonni, R.6
  • 96
    • 12244271026 scopus 로고    scopus 로고
    • Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups
    • Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12(9): 725-33.
    • (2002) Pharmacogenetics , vol.12 , Issue.9 , pp. 725-733
    • Innocenti, F.1    Grimsley, C.2    Das, S.3    Ramirez, J.4    Cheng, C.5    Kuttab-Boulos, H.6
  • 98
    • 14044279224 scopus 로고    scopus 로고
    • Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American
    • Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos 2005; 33(3): 458-65.
    • (2005) Drug Metab Dispos , vol.33 , Issue.3 , pp. 458-465
    • Kaniwa, N.1    Kurose, K.2    Jinno, H.3    Tanaka-Kagawa, T.4    Saito, Y.5    Saeki, M.6
  • 99
    • 3242769758 scopus 로고    scopus 로고
    • Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
    • Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 2004; 44(8): 854-60.
    • (2004) J Clin Pharmacol , vol.44 , Issue.8 , pp. 854-860
    • Paoluzzi, L.1    Singh, A.S.2    Price, D.K.3    Danesi, R.4    Mathijssen, R.H.5    Verweij, J.6
  • 100
    • 4143101374 scopus 로고    scopus 로고
    • Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients
    • Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10(15): 5151-9.
    • (2004) Clin Cancer Res , vol.10 , Issue.15 , pp. 5151-5159
    • Rouits, E.1    Boisdron-Celle, M.2    Dumont, A.3    Guerin, O.4    Morel, A.5    Gamelin, E.6
  • 101
    • 4344632633 scopus 로고    scopus 로고
    • UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
    • Marcuello E, Altes A, Menoyo A, del RE, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91(4): 678-82.
    • (2004) Br J Cancer , vol.91 , Issue.4 , pp. 678-682
    • Marcuello, E.1    Altes, A.2    Menoyo, A.3    del, R.E.4    Gomez-Pardo, M.5    Baiget, M.6
  • 102
    • 48249145381 scopus 로고    scopus 로고
    • UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: A Dutch Colorectal Cancer Group study
    • Kweekel DM, Gelderblom H, Van der ST, Antonini NF, Punt CJ, Guchelaar HJ. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 2008; 99(2): 275-82.
    • (2008) Br J Cancer , vol.99 , Issue.2 , pp. 275-282
    • Kweekel, D.M.1    Gelderblom, H.2    Van der, S.T.3    Antonini, N.F.4    Punt, C.J.5    Guchelaar, H.J.6
  • 103
    • 33745972934 scopus 로고    scopus 로고
    • The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
    • Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24(19): 3061-8.
    • (2006) J Clin Oncol , vol.24 , Issue.19 , pp. 3061-3068
    • Toffoli, G.1    Cecchin, E.2    Corona, G.3    Russo, A.4    Buonadonna, A.5    D'Andrea, M.6
  • 104
    • 34250614001 scopus 로고    scopus 로고
    • UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy
    • Ando Y, Fujita K, Sasaki Y, Hasegawa Y. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther 2007; 9(3): 258-62.
    • (2007) Curr Opin Mol Ther , vol.9 , Issue.3 , pp. 258-262
    • Ando, Y.1    Fujita, K.2    Sasaki, Y.3    Hasegawa, Y.4
  • 105
    • 0021852930 scopus 로고
    • Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies
    • Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985; 316(6031): 820-3.
    • (1985) Nature , vol.316 , Issue.6031 , pp. 820-823
    • Kartner, N.1    Evernden-Porelle, D.2    Bradley, G.3    Ling, V.4
  • 106
    • 0036667956 scopus 로고    scopus 로고
    • Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations
    • Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12(6): 437-50.
    • (2002) Pharmacogenetics , vol.12 , Issue.6 , pp. 437-450
    • Tang, K.1    Ngoi, S.M.2    Gwee, P.C.3    Chua, J.M.4    Lee, E.J.5    Chong, S.S.6
  • 107
    • 3042772026 scopus 로고    scopus 로고
    • Identification of functionally variant MDR1 alleles among European Americans and African Americans
    • Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70(2): 189-99.
    • (2001) Clin Pharmacol Ther , vol.70 , Issue.2 , pp. 189-199
    • Kim, R.B.1    Leake, B.F.2    Choo, E.F.3    Dresser, G.K.4    Kubba, S.V.5    Schwarz, U.I.6
  • 108
    • 11344272181 scopus 로고    scopus 로고
    • Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer
    • Wong M, Evans S, Rivory LP, Hoskins JM, Mann GJ, Farlow D, et al. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther 2005; 77(1): 33-42.
    • (2005) Clin Pharmacol Ther , vol.77 , Issue.1 , pp. 33-42
    • Wong, M.1    Evans, S.2    Rivory, L.P.3    Hoskins, J.M.4    Mann, G.J.5    Farlow, D.6
  • 109
    • 33746829167 scopus 로고    scopus 로고
    • Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: An expanded haplotype block covering the distal promoter region, and associated ethnic differences
    • Sai K, Itoda M, Saito Y, Kurose K, Katori N, Kaniwa N, et al. Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, and associated ethnic differences. Ann Hum Genet 2006; 70(Pt 5): 605-22.
    • (2006) Ann Hum Genet , vol.70 , Issue.PART 5 , pp. 605-622
    • Sai, K.1    Itoda, M.2    Saito, Y.3    Kurose, K.4    Katori, N.5    Kaniwa, N.6
  • 110
    • 17144413348 scopus 로고    scopus 로고
    • Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer
    • Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, Poon D, et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 2005; 59(4): 415-24.
    • (2005) Br J Clin Pharmacol , vol.59 , Issue.4 , pp. 415-424
    • Zhou, Q.1    Sparreboom, A.2    Tan, E.H.3    Cheung, Y.B.4    Lee, A.5    Poon, D.6
  • 112
    • 4444381535 scopus 로고    scopus 로고
    • ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition
    • de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004; 10(17): 5889-94.
    • (2004) Clin Cancer Res , vol.10 , Issue.17 , pp. 5889-5894
    • de Jong, F.A.1    Marsh, S.2    Mathijssen, R.H.3    King, C.4    Verweij, J.5    Sparreboom, A.6
  • 115
    • 0024509906 scopus 로고
    • Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors
    • Moscow JA, Fairchild CR, Madden MJ, Ransom DT, Wieand HS, O'Brien EE, et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989; 49(6): 1422-8.
    • (1989) Cancer Res , vol.49 , Issue.6 , pp. 1422-1428
    • Moscow, J.A.1    Fairchild, C.R.2    Madden, M.J.3    Ransom, D.T.4    Wieand, H.S.5    O'Brien, E.E.6
  • 116
    • 0034667365 scopus 로고    scopus 로고
    • Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism
    • Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000; 60(20): 5621-4.
    • (2000) Cancer Res , vol.60 , Issue.20 , pp. 5621-5624
    • Sweeney, C.1    McClure, G.Y.2    Fares, M.Y.3    Stone, A.4    Coles, B.F.5    Thompson, P.A.6
  • 117
    • 0037134707 scopus 로고    scopus 로고
    • Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer
    • Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94(12): 936-42.
    • (2002) J Natl Cancer Inst , vol.94 , Issue.12 , pp. 936-942
    • Stoehlmacher, J.1    Park, D.J.2    Zhang, W.3    Groshen, S.4    Tsao-Wei, D.D.5    Yu, M.C.6
  • 118
    • 3843130823 scopus 로고    scopus 로고
    • A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
    • Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91(2): 344-54.
    • (2004) Br J Cancer , vol.91 , Issue.2 , pp. 344-354
    • Stoehlmacher, J.1    Park, D.J.2    Zhang, W.3    Yang, D.4    Groshen, S.5    Zahedy, S.6
  • 119
    • 30444435538 scopus 로고    scopus 로고
    • Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival
    • Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 2006; 100(2): 330-7.
    • (2006) Gynecol Oncol , vol.100 , Issue.2 , pp. 330-337
    • Beeghly, A.1    Katsaros, D.2    Chen, H.3    Fracchioli, S.4    Zhang, Y.5    Massobrio, M.6
  • 120
    • 0035476887 scopus 로고    scopus 로고
    • Polymorphisms in glutathione Stransferases (GSTM1 and GSTT1) and survival after treatment for breast cancer
    • Ambrosone CB, Sweeney C, Coles BF, Thompson PA, McClure GY, Korourian S, et al. Polymorphisms in glutathione Stransferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 2001; 61(19): 7130-5.
    • (2001) Cancer Res , vol.61 , Issue.19 , pp. 7130-7135
    • Ambrosone, C.B.1    Sweeney, C.2    Coles, B.F.3    Thompson, P.A.4    McClure, G.Y.5    Korourian, S.6
  • 121
    • 33744787046 scopus 로고    scopus 로고
    • Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy
    • Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12(10): 3050-6.
    • (2006) Clin Cancer Res , vol.12 , Issue.10 , pp. 3050-3056
    • Lecomte, T.1    Landi, B.2    Beaune, P.3    Laurent-Puig, P.4    Loriot, M.A.5
  • 122
    • 0028018885 scopus 로고
    • Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage
    • Larminat F, Bohr VA. Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res 1994; 22(15): 3005-10.
    • (1994) Nucleic Acids Res , vol.22 , Issue.15 , pp. 3005-3010
    • Larminat, F.1    Bohr, V.A.2
  • 123
    • 33847681504 scopus 로고    scopus 로고
    • Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
    • Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18(3): 522-8.
    • (2007) Ann Oncol , vol.18 , Issue.3 , pp. 522-528
    • Bellmunt, J.1    Paz-Ares, L.2    Cuello, M.3    Cecere, F.L.4    Albiol, S.5    Guillem, V.6
  • 124
    • 4444256594 scopus 로고    scopus 로고
    • Single nucleotide polymorphisms and outcome in docetaxelcisplatin-treated advanced non-small-cell lung cancer
    • Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxelcisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15(8): 1194-203.
    • (2004) Ann Oncol , vol.15 , Issue.8 , pp. 1194-1203
    • Isla, D.1    Sarries, C.2    Rosell, R.3    Alonso, G.4    Domine, M.5    Taron, M.6
  • 125
    • 24344479165 scopus 로고    scopus 로고
    • ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemo-therapy in patients with advanced colorectal cancer
    • Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemo-therapy in patients with advanced colorectal cancer. Clin Cancer Res 2005; 11(17): 6212-7.
    • (2005) Clin Cancer Res , vol.11 , Issue.17 , pp. 6212-6217
    • Viguier, J.1    Boige, V.2    Miquel, C.3    Pocard, M.4    Giraudeau, B.5    Sabourin, J.C.6
  • 126
    • 53049110722 scopus 로고    scopus 로고
    • Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
    • Pare L, Marcuello E, Altes A, del RE, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 2008; 99(7): 1050-5.
    • (2008) Br J Cancer , vol.99 , Issue.7 , pp. 1050-1055
    • Pare, L.1    Marcuello, E.2    Altes, A.3    del, R.E.4    Sedano, L.5    Salazar, J.6
  • 127
    • 0035866403 scopus 로고    scopus 로고
    • Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients
    • Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61(4): 1354-7.
    • (2001) Cancer Res , vol.61 , Issue.4 , pp. 1354-1357
    • Spitz, M.R.1    Wu, X.2    Wang, Y.3    Wang, L.E.4    Shete, S.5    Amos, C.I.6
  • 128
    • 4344567395 scopus 로고    scopus 로고
    • XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
    • Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22(13): 2594-601.
    • (2004) J Clin Oncol , vol.22 , Issue.13 , pp. 2594-2601
    • Gurubhagavatula, S.1    Liu, G.2    Park, S.3    Zhou, W.4    Su, L.5    Wain, J.C.6
  • 129
    • 0035893755 scopus 로고    scopus 로고
    • A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer
    • Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61(24): 8654-8.
    • (2001) Cancer Res , vol.61 , Issue.24 , pp. 8654-8658
    • Park, D.J.1    Stoehlmacher, J.2    Zhang, W.3    Tsao-Wei, D.D.4    Groshen, S.5    Lenz, H.J.6
  • 130
    • 33748324572 scopus 로고    scopus 로고
    • Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy
    • Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 2006; 95(5): 561-70.
    • (2006) Br J Cancer , vol.95 , Issue.5 , pp. 561-570
    • Sakano, S.1    Wada, T.2    Matsumoto, H.3    Sugiyama, S.4    Inoue, R.5    Eguchi, S.6
  • 131
    • 2342616723 scopus 로고    scopus 로고
    • Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy
    • Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44(3): 311-6.
    • (2004) Lung Cancer , vol.44 , Issue.3 , pp. 311-316
    • Ryu, J.S.1    Hong, Y.C.2    Han, H.S.3    Lee, J.E.4    Kim, S.5    Park, Y.M.6
  • 132
    • 47349119840 scopus 로고    scopus 로고
    • Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
    • Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 2008; 8: 148.
    • (2008) BMC Cancer , vol.8 , pp. 148
    • Keam, B.1    Im, S.A.2    Han, S.W.3    Ham, H.S.4    Kim, M.A.5    Oh, D.Y.6
  • 133
    • 35848930119 scopus 로고    scopus 로고
    • Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein
    • Monaco R, Rosal R, Dolan MA, Pincus MR, Brandt-Rauf PW. Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J 2007; 26(8): 541-6.
    • (2007) Protein J , vol.26 , Issue.8 , pp. 541-546
    • Monaco, R.1    Rosal, R.2    Dolan, M.A.3    Pincus, M.R.4    Brandt-Rauf, P.W.5
  • 134
    • 33749036570 scopus 로고    scopus 로고
    • DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy
    • Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006; 24(26): 4333-9.
    • (2006) J Clin Oncol , vol.24 , Issue.26 , pp. 4333-4339
    • Quintela-Fandino, M.1    Hitt, R.2    Medina, P.P.3    Gamarra, S.4    Manso, L.5    Cortes-Funes, H.6
  • 135
    • 34848912861 scopus 로고    scopus 로고
    • Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population
    • Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, et al. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 2007; 15(10): 1049-53.
    • (2007) Eur J Hum Genet , vol.15 , Issue.10 , pp. 1049-1053
    • Liu, B.1    Wei, J.2    Zou, Z.3    Qian, X.4    Nakamura, T.5    Zhang, W.6
  • 136
    • 0035174375 scopus 로고    scopus 로고
    • A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer
    • Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21(4B): 3075-9.
    • (2001) Anticancer Res , vol.21 , Issue.4 B , pp. 3075-3079
    • Stoehlmacher, J.1    Ghaderi, V.2    Iobal, S.3    Groshen, S.4    Tsao-Wei, D.5    Park, D.6
  • 137
    • 18544389188 scopus 로고    scopus 로고
    • The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver
    • Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002; 54(2): 157-67.
    • (2002) Br J Clin Pharmacol , vol.54 , Issue.2 , pp. 157-167
    • Coller, J.K.1    Krebsfaenger, N.2    Klein, K.3    Endrizzi, K.4    Wolbold, R.5    Lang, T.6
  • 138
    • 0033017135 scopus 로고    scopus 로고
    • Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: Involvement of catechols in covalent binding to hepatic proteins
    • Dehal SS, Kupfer D. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 1999; 27(6): 681-8.
    • (1999) Drug Metab Dispos , vol.27 , Issue.6 , pp. 681-688
    • Dehal, S.S.1    Kupfer, D.2
  • 139
    • 33644639136 scopus 로고    scopus 로고
    • Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
    • Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23(36): 9312-8.
    • (2005) J Clin Oncol , vol.23 , Issue.36 , pp. 9312-9318
    • Goetz, M.P.1    Rae, J.M.2    Suman, V.J.3    Safgren, S.L.4    Ames, M.M.5    Visscher, D.W.6
  • 140
    • 29144491089 scopus 로고    scopus 로고
    • Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
    • Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005; 7(3): R284-90.
    • (2005) Breast Cancer Res , vol.7 , Issue.3
    • Wegman, P.1    Vainikka, L.2    Stal, O.3    Nordenskjold, B.4    Skoog, L.5    Rutqvist, L.E.6
  • 141
    • 33745347897 scopus 로고    scopus 로고
    • Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment
    • Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80(1): 61-74.
    • (2006) Clin Pharmacol Ther , vol.80 , Issue.1 , pp. 61-74
    • Borges, S.1    Desta, Z.2    Li, L.3    Skaar, T.C.4    Ward, B.A.5    Nguyen, A.6
  • 142
    • 19944434201 scopus 로고    scopus 로고
    • CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    • Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97(1): 30-9.
    • (2005) J Natl Cancer Inst , vol.97 , Issue.1 , pp. 30-39
    • Jin, Y.1    Desta, Z.2    Stearns, V.3    Ward, B.4    Ho, H.5    Lee, K.H.6
  • 143
    • 53249140840 scopus 로고    scopus 로고
    • Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: Combining inherited and tumor gene markers for prediction of tamoxifen resistance
    • Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, et al. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 2008; 14(18): 5864-8.
    • (2008) Clin Cancer Res , vol.14 , Issue.18 , pp. 5864-5868
    • Goetz, M.P.1    Suman, V.J.2    Couch, F.J.3    Ames, M.M.4    Rae, J.M.5    Erlander, M.G.6
  • 145
    • 34248208754 scopus 로고    scopus 로고
    • Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
    • Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007; 9(1): R7.
    • (2007) Breast Cancer Res , vol.9 , Issue.1
    • Wegman, P.1    Elingarami, S.2    Carstensen, J.3    Stal, O.4    Nordenskjold, B.5    Wingren, S.6
  • 147
    • 0035871980 scopus 로고    scopus 로고
    • Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizing enzymes and gene-environment interactions
    • Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, et al. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer 2001; 92(2): 220-5.
    • (2001) Int J Cancer , vol.92 , Issue.2 , pp. 220-225
    • Krajinovic, M.1    Ghadirian, P.2    Richer, C.3    Sinnett, H.4    Gandini, S.5    Perret, C.6
  • 148
    • 0032537990 scopus 로고    scopus 로고
    • Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    • Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90(18): 1371-88.
    • (1998) J Natl Cancer Inst , vol.90 , Issue.18 , pp. 1371-1388
    • Fisher, B.1    Costantino, J.P.2    Wickerham, D.L.3    Redmond, C.K.4    Kavanah, M.5    Cronin, W.M.6
  • 149
    • 58849087666 scopus 로고    scopus 로고
    • Dezentje VO, Guchelaar HJ, Nortier JW, van d V, Gelderblom H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 2009; 15(1): 15-21.
    • Dezentje VO, Guchelaar HJ, Nortier JW, van d V, Gelderblom H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 2009; 15(1): 15-21.
  • 151
    • 57349167712 scopus 로고    scopus 로고
    • Pharmacogenetics and pharmagenomics, trends in normal and pathological aging studies: Focus on p53
    • Lanni C, Racchi M, Uberti D, Mazzini G, Stanga S, Sinforiani E, et al. Pharmacogenetics and pharmagenomics, trends in normal and pathological aging studies: focus on p53. Curr Pharm Des 2008; 14(26): 2665-71.
    • (2008) Curr Pharm Des , vol.14 , Issue.26 , pp. 2665-2671
    • Lanni, C.1    Racchi, M.2    Uberti, D.3    Mazzini, G.4    Stanga, S.5    Sinforiani, E.6
  • 152
    • 57349114902 scopus 로고    scopus 로고
    • Pro-inflammatory gene variants in myocardial infarction and longevity: Implications for pharmacogenomics
    • Listi F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CR, et al. Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des 2008; 14(26): 2678-85.
    • (2008) Curr Pharm Des , vol.14 , Issue.26 , pp. 2678-2685
    • Listi, F.1    Caruso, M.2    Incalcaterra, E.3    Hoffmann, E.4    Caimi, G.5    Balistreri, C.R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.